Regeneron Pharmaceuticals
- Market cap
- 76.40B
- P/E (TTM)i
- 18.36
- P/Bi
- 2.41
- EPSi
- 41.48
- Div yieldi
- 0.49%
- 52W posi
- 63%
Anonymous reader poll. Unscientific, not investment advice.
Regeneron Pharmaceuticals last traded at 742.12, up 0.46% on the session. Its market capitalisation is about 76.40B, the #285 most valuable US-listed company we track. Trading at a P/E of 17.98, the stock is broadly in line with its own five-year norm of 18.13. It pays a dividend yielding 0.49% on a trailing basis. Wall Street's 19-analyst consensus lands on Buy, with a price target averaging 841.37 (+13% from here). Against a 52-week band of 538.24-859.34, the shares are currently 63% of the way up.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 day.
- Recent price momentum is +18.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 2.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 18.0x | Better than 53% |
| Forward P/E | 13.9x | Better than 64% |
| Price / Sales | 5.2x | Better than 27% |
| P/E vs own 5-yr range | 63rd pctl | Better than 47% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 5.6% | Better than 46% |
| Net income CAGR (3Y) | 1.3% | Better than 41% |
| Free cash flow CAGR (3Y) | 3.5% | Better than 39% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 85.4% | Better than 95% |
| Operating margin | 25.8% | Better than 78% |
| Net margin | 31.4% | Better than 91% |
| Return on equity | 14.9% | Better than 55% |
| Return on invested capital | 11.9% | Better than 63% |
Momentum B
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 7.6% | Better than 71% |
| 6-month return | -4.2% | Better than 32% |
| 12-month return (ex latest month) | 42.1% | Better than 76% |
| Distance below 52-week high | 15.5% | Better than 58% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.1x | Better than 90% |
| Debt to assets | 8.7% | Better than 80% |
| Interest coverage | 120.4x | Better than 93% |
| Free cash flow / net income | 83.6% | Better than 28% |
Analyst View C
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 63.2% | Better than 38% |
| Upside to average target | 15.8% | Better than 29% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 738.72
- Open
- 738.05
- Day range
- 734.18 - 753.68
- Avg price
- 743.98
- Volume
- 626.43K
- Turnover
- 466.05M
- Turnover ratei
- 0.63%
- Volume ratioi
- 0.82
- Amplitudei
- 2.64%
- 52-week rangei
- 538.24 - 859.34
Valuation
- P/Ei
- 17.89
- P/E (TTM)i
- 18.36
- P/Bi
- 2.41
- EPSi
- 41.48
- Book value / shi
- 308.01
- Net profit
- 4.27B
- Net assets
- 31.71B
Share structure
- Market cap
- 76.40B
- Float capi
- 73.43B
- Shares out
- 102.95M
- Float sharesi
- 98.95M
Dividend & listing
- Div yield (TTM)i
- 0.49%
- Dividend (TTM)
- 3.64
- Listing date
- 1970-01-01
13.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+47.76M net over the window
Short interest
- Shares short
- 2.53M
- % of floati
- 2.45%
- Days to coveri
- 4.42
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals last traded at 742.12. The quote on this page refreshes every few seconds while US markets are open.
What is Regeneron Pharmaceuticals's market cap?
About 76.40B.
What is the P/E ratio of Regeneron Pharmaceuticals?
The trailing twelve-month P/E is 18.36, above its own 5-year average of 18.13 — in the middle of its historical range (50.84% percentile). See the Valuation tab for the full history.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. The trailing dividend yield is 0.49%. See the Dividends tab for the full payment history.
Is Regeneron Pharmaceuticals a buy according to analysts?
The consensus of 19 analysts is a Buy rating, with an average 12-month price target of 841.37, which implies 13.4% upside from the current price. This is not investment advice.
What is Regeneron Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Regeneron Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 05:13:24 · For reference only, not investment advice and not tailored to your situation.